FDA slaps a partial clinical hold for unwanted side effects, now what?
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18
